Navigation Links
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/10/2013

SAN DIEGO, May 10, 2013  /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 2:20 p.m. Pacific Time (5:20 p.m. Eastern Time), at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, is approved in the United States, and is under review for regulatory approval in additional territories. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCert
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
2. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
3. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
6. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
7. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
9. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
10. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
11. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... The U.S. Food and Drug Administration is requiring ... on their labels about the risk of a ... systemic fibrosis (NSF), if the drug is administered ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo:   ...
... (Nasdaq: MSON ), a developer of ... which worldwide is used for acute health conditions, ... distribution agreement with Dismeval, s.l.,  based in Valencia, ... Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone ...
Cached Medicine Technology:FDA: New Warnings Required on Use of Gadolinium-Based Contrast Agents 2Misonix Announces New Distribution Agreement For Spain 2Misonix Announces New Distribution Agreement For Spain 3
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... prescriptions from Jan 1 - June 30, 2009; BCBSNC,s 2008 "Medication Dedication" ... of $13 million on out-of-pocket costs; The 2009 generic copay waiver program ... ... (Vocus) December 8, 2008 -- Blue Cross and Blue Shield of ...
... Leaders Join the Faces of Influenza Campaign to Promote Annual ... Association Supports National Influenza Vaccination Week (December 8-14); Urges Immunization ... , CLEVELAND, Dec. 8 Health experts recommend ... U.S. Despite this recommendation, influenza immunization rates fall far short ...
... availability,of Trade Alerts on stocks making news today. , ... trading notes for free by visiting:, http://www.BeaconEquity.com/m , ... HCP ), Healthcare Realty,Trust (NYSE: HR ), ... (NYSE: UHT ), Nationwide Health Properties Inc. (NYSE: ...
... Start Exploring Their Shared Genetics , ... Mountain View, CA (PRWEB) December ... genetics, today announced it is offering a Multiple Kit discount ... a single order will save $200 on the first three kits and ...
... world,s first 12mm AirSeal single incision laparoscopic supracervical hysterectomy ... Hospital in Cambridge, MA. Dr. Tony DiSciullo and ... 12mm access port in the abdomen. The AirSeal(TM) ... contained within the cannula and does not rely on ...
... on Health and Pharmacy Outcomes Specialists collaborate to produce second ... Dec. 8 The Midwest Business Group on Health (MBGH) ... second annual Pharmacy Benefits Academy (PBA) to be held at ... collaboration between MBGH and POS, the Academy is part of ...
Cached Medicine News:Health News:BCBSNC Helps Customers Fight Recession With Free Generics 2Health News:BCBSNC Helps Customers Fight Recession With Free Generics 3Health News:BCBSNC Helps Customers Fight Recession With Free Generics 4Health News:The American Lung Association of Ohio Encourages Cleveland Residents to See Themselves Among The Many 'Faces' of Influenza 2Health News:The American Lung Association of Ohio Encourages Cleveland Residents to See Themselves Among The Many 'Faces' of Influenza 3Health News:The American Lung Association of Ohio Encourages Cleveland Residents to See Themselves Among The Many 'Faces' of Influenza 4Health News:Beacon Equity Issues Technical Trade Alerts on REIT Healthcare Facilities: HCP, HR, VTR, UHT, NHP, NHI 2Health News:23andMe Announces Holiday Season Multi-Pack Discount 2Health News:23andMe Announces Holiday Season Multi-Pack Discount 3Health News:SurgiQuest Announces First Single Port Procedure for Uterus and Ovary Removal Using AirSeal(TM) Access System 2Health News:Pharmacy Benefits Academy Set for 2009 2Health News:Pharmacy Benefits Academy Set for 2009 3
... The D.O.R.C. Associate® is an advanced ... Peristaltic and Venturi pump, allowing surgeons ... for Phaco or Vitrectomy procedures.,The key ... a microprocessor-controlled vacuum system that measures ...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
Red Rubber Robinson Catheters (Latex)...
Medicine Products: